Sector consensus Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
20:57:38 14/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 52.51 USD | -1.04% |
|
-0.77% | +19.21% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 60.38 | +14.96% | 16 | ||||||
| 182.53 | +14.63% | 18 | ||||||
| - | - | 1,229.81 | +45.47% | 1 | ||||
| 200.05 | +61.67% | 22 | ||||||
| 40.85 | +5.3% | 23 | ||||||
| 104.26 | +29.48% | 20 | ||||||
| 1,216.34 | -18.91% | 7 | ||||||
| 2,410.59 | +18.92% | 15 | ||||||
| 570.05 | +9.52% | 18 | ||||||
| 52.94 | +3.31% | 16 | ||||||
| 110.18 | +27.17% | 11 | ||||||
| 678.06 | +33.59% | 16 | ||||||
| 144.21 | +74.81% | 21 | ||||||
| 21.11 | +113.53% | 13 | ||||||
| 109.9 | +48.25% | 20 | ||||||
| 124.71 | +20.35% | 14 | ||||||
| 99.56 | +43.57% | 16 | ||||||
| 85.5 | +0.94% | 10 | ||||||
| 109 | +87.7% | 9 | ||||||
| - | - | - | - | - | ||||
| Average | 397.37 | +33.38% | 15 | ||||||
| Weighted average by Cap. | 501.52 | +29.85% | 15 |
- Stock Market
- Stocks
- SRRK Stock
- Sector Scholar Rock Holding Corporation
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
